$CODX

Co-Diagnostics secured up to $3.1M in senior secured convertible notes from J.J. Astor & Co., with $2.1M initially funded. The notes have a 1.35x factor, 30 weekly installments, and are backed by a senior-priority lien and subsidiary guarantees. The company also agreed to an ATM proceeds waterfall and a registration rights deal for resale of conversion-related shares. Maxim Group was engaged as placement agent.

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Loan Transaction with J.J. Astor & Co. On October 9, 2026, Co-Diagnostics, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with J.J. Astor & Co. (the “Lender”), pursuant to

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did not achieve a quorum a

Codexis (CODX) partnered with a siRNA drug developer to evaluate its ECO Synthesis platform for manufacturing RNA therapies. The collaboration will compare the platform's performance with conventional methods, focusing on purity and quality. Codexis aims to advance scalable manufacturing solutions for oligonucleotide therapeutics. The stock is currently trading at $1.36, up 3.41%.

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. As previously announced on September 4, 2026, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did n

Co-Diagnostics, Inc. and other defendants have agreed to a $6.5M settlement in a class action lawsuit. The suit involves investors who traded the company's stock or options between May 12, 2022, and August 11, 2022. A hearing to approve the settlement is scheduled for December 8, 2026. Class members must submit claims by January 6, 2027, to share in the settlement fund.

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Co-Diagnostics, Inc. (the “Company”) and Brian Brown, the Company’s Chief Financial Officer, determi

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did not achieve a quorum and therefore was unable t

Co-Diagnostics (CODX) reported Q2 2026 revenue of $166,131, a slight increase from the previous quarter, with a net loss of $6.3 million, narrowed from $7.7 million. The company highlighted progress in FDA submissions, strategic initiatives, and cost reductions. Management emphasized focus on clinical pipeline and regulatory submissions despite near-term operating losses.

Co-Diagnostics (Nasdaq: CODX) said its Chief Commercialization Officer participated in Salt Lake Business Journal’s 2026 Medical Devices and Innovation Roundtable on Aug. 13. The company also disclosed a 510(k) premarket notification submission to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument, pending FDA clearance.